SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4.
Wong DVT, Ribeiro-Filho HV, Wanderley CWS, Leite CAVG, Lima JB, Assef ANB, Cajado AG, Batista GLP, González RH, Silva KO, Borges LPC, Alencar NMN, Wilke DV, Cunha TM, Figueira ACM, Cunha FQ, Lima-Júnior RCP.
Wong DVT, et al. Among authors: lima jb, lima junior rcp.
Cancer Chemother Pharmacol. 2019 Aug;84(2):287-298. doi: 10.1007/s00280-019-03844-z. Epub 2019 Apr 22.
Cancer Chemother Pharmacol. 2019.
PMID: 31011814